Imophoron is changing the way we make vaccines, to provide the world with the next-generation of therapeutics for unmet medical needs and future threats.
Imophoron has created novel vaccines based on the ADDomer™ platform to provide protection against infectious disease wherever it affects human health across the world.
We are a pre-clinical stage company with a novel next generation nanoparticle vaccine platform called ADDomer™. ADDomer™ is a patented technology for creating highly immunogenic vaccine candidates and is a multimeric protein-based, self-assembling nanoparticle scaffold. Proof of concept data for two highly infectious diseases demonstrates potential to prevent disease and transmission. The ADDomer™ platform also has significant potential to generate therapeutic candidates to treat disease with high unmet need such us oncology.